30th April 2019: Rosacea is a common skin condition characterized by visible blood vessels and redness on the cheeks and nose. The signs and symptoms of rosacea are formation of red, small, pus-filled bumps, which may flare up repeatedly. Around half of the patients suffer from irritation of eyelids and redness, swelling, dryness in the eye. Other symptoms comprise of enlargement and thickening of skin on the nose (rhinophyma). The disease is mainly observed in middle-aged women having fair skin tone.
Strong Competition from Off-label Drugs
The major drug class-variants of rosacea treatment include alpha agonists, antibiotics, corticosteroids, retinoids, antihypertensive agents, immunosuppressants, and others. Antibiotics are commonly used as the first line of treatment. One of the most commonly prescribed antibiotics for rosacea is Metronidazole.
Some of the other antibiotics used in rosacea treatment comprise of erythromycin, clarithromycin, clindamycin, doxycycline, tetracycline, minocycline, azelaic acid, and sulfacetamide products are suggested in the first line of therapy. Immunosuppressants, like tacrolimus, are also used to decrease itching and inflammation by suppressing cytokines.
The alpha agonists segment is the fastest growing drug class and is anticipated to grow high in the forecast period. The key factor attributed to the growth of the market is high demand from the consumers. The alpha agonists class has two key revenue generators, namely, Rhofade and Mirvaso. Both the products are specified for rosacea-associated erythema.
Market Insights
The market is expected to face strong competition throughout the forthcoming period due to the existence of multinational establishments. Leading players operating in the rosacea treatment market include Bayer Schering AG; Allergan Plc; Nestlé S.A.; and Bausch Health Companies Inc.
The market is driven by the expected launch of promising pipeline applicants from Sol-Gel Technologies and Foamix Pharmaceuticals. Novel product development, joint ventures, and geographical expansion are some of the important policies accepted by significant market players.
Nestlé S.A. (Galderma section) led the competitive space and is predicted to continue holding the major market share, supported by the strong commercial performances of Oracea, Mirvaso, Soolantra, and Metro Gel. In addition, Rhofade from Noritate and Allergan from Bausch are important revenue contributors.
No comments:
Post a Comment